Since its inception, ENDORENEW has been at the forefront of medical research and therapeutic development for both Asherman syndrome (AS) and thin endometrium (TE). The company’s commitment to advancing scientific understanding and treatment options for these conditions is reflected in its significant milestones, starting from early clinical trials to cutting-edge research publications. Below is a timeline that outlines the key achievements and ongoing efforts that have defined PAULA’s journey.
First trial group using autologous CD133+ . Trial on efficacy and safety of the therapy.
Status assigned to CD133+ for the treatment of AS, considered a rare disease.
20 patients were recruited to assess the effects of the stem cell treatment under a controlled environment. The Phase I/II study was completed in 2024, with results published in 2026 in a high impact journal.
After its submission in 2015, the patent of stem cell therapy to treat AS was granted in 2021. The invention relates to the use of autologous CD133+ bone marrow derived stem cells to treat endometrial pathologies.
We obtained the landscape of AS endometrium at single cell level by analyzing data from over 200,000 cells from single-cell RNA-sequencing in patients (Nat. Comm, 2023).
Planned to start in Spain on Q3.
European Commission. (2017). Community Register of medicinal products for human use. Retrieved from https://ec.europa.eu/health/documents/community-register/html/mh26147.htm
Google Patents. (2021). Patent US11129851B2. Retrieved from https://patents.google.com/patent/US11129851B2/de
Santamaria, X., Roson, B., Perez-Moraga, R., Venkatesan, N., Pardo-Figuerez, M., Gonzalez-Fernandez, J., Llera-Oyola, J., Fernández, E., Moreno, I., Salumets, A., Vankelecom, H., Vilella, F., & Simon, C. (2023). Decoding the endometrial niche of Asherman’s syndrome at single-cell resolution. Nature communications, 14(1), 5890. https://doi.org/10.1038/s41467-023-41656-1
Santamaria, X., Cabanillas, S., Cervelló, I., Arbona, C., Raga, F., Ferro, J., Palmero, J., Remohí, J., Pellicer, A., & Simón, C. (2016). Autologous cell therapy with CD133+ bone marrow-derived stem cells for refractory Asherman’s syndrome and endometrial atrophy: a pilot cohort study. Human reproduction (Oxford, England), 31(5), 1087–1096. https://doi.org/10.1093/humrep/dew042
Endorenew has received funding from:
The Torres Quevedo Program 2022 of the Ministry of Science and Innovation (reference number PTQ2022-012376) for the project titled «Application of New Embryo Transfer Methodologies for the Improvement of Reproductive Prognosis in Severe Cases of Asherman’s Syndrome,» with a grant of €114,674 for the period 2024-2027.
